Prostate cancer (PCa)bone metastases are unique in that majority of them induce excessive mineralized bone matrix, through undefined mechanisms, as opposed to most other cancers that induce bone resorption. Parathyroid hormone-related protein (PTHrP) is produced by PCa cells and intermittent PTHrP exposure has bone anabolic effects, suggesting that PTHrP could contribute to the excess bone mineralization. Wnts are bone-productive factors produced by PCa cells, and the Wnt inhibitor Dickkopfs-1 (DKK1) has been shown to promote PCa progression. These findings, in conjunction with the observation that PTHrP expression increases and DKK1 expression decreases as PCa progresses, led to the hypothesis that PTHrP could be a negative regulator of DKK1 expression in PCa cells and, hence, allow the osteoblastic activity of Wnts to be realized. To test this, we first demonstrated that PTHrP downregulated DKK1 mRNA and protein expression. We then found through multiple mutated DKK1 promoter assays that PTHrP, through c-Jun activation, downregulated the DKK1 promoter through a transcription factor (TCF) response element site. Furthermore, chromatin immunoprecipitation (ChIP) and re-ChIP assays revealed that PTHrP mediated this effect through inducing c-Jun to bind to a transcriptional activator complex consisting of b-catenin, which binds the most proximal DKK1 promoter, the TCF response element. Together, these results demonstrate a novel signaling linkage between PTHrP and Wnt signaling pathways that results in downregulation of a Wnt inhibitor allowing for Wnt activity that could contribute the osteoblastic nature of PCa.
INTRODUCTION
Prostate cancer (PCa), a frequently occurring cancer of men in western countries, leads to bone metastases in over 90% of patients with progressive disease. In contrast to the majority of bone metastatic tumors that produce primarily osteolytic (that is, bone resorptive) lesions, PCa produces primarily osteoblastic (that is, bone productive) lesions (reviewed in Weilbacher et al. 1 
and Keller and Brown 2
). The mechanisms through which PCa promotes osteoblastic lesions are not clearly defined. Elucidation of these underlying mechanisms holds promise for the identification of therapeutic targets that will benefit PCa patients.
Cellular signaling pathways are important in onset, early progression and metastasis of multiple cancers, and thus offer a fertile area for research. The Wnt signaling pathway has been shown to have a major role in the early events of tumor initiation in colon cancer. However, less is known regarding the role of Wnts once a tumor is established. The Wnt family contains 19 secreted homolog Wnt proteins, 10 Frizzled receptors, two low-density lipoprotein-related proteins 5 and 6(LRP5/6), and inhibitory antagonists such as WNT inhibitory factor (WIF), Dickkopfs (DKK) and secreted Frizzled-related protein. 3, 4 Wnt signaling is divided into two pathways, the canonical pathway that invokes activation of b-catenin/transcription factor(TCF) target gene activation and the non-canonical pathway that induces signaling independent of b-catenin. 5 The key role that Wnt signaling has in bone biology suggests that the Wnt pathway may have a role in PCa bone metastasis. Along these lines, we have previously identified that PCa produces many Wnts as well as the Wnt inhibitor DKK1, which diminishes PCa-induced osteoblastic activity through blocking Wnt activity. 6 More recently, we identified that as PCa progresses from primary tumors to metastases in clinical PCa tissues, DKK1 expression decreases, which could allow Wnt activity to manifest and account for the osteoblastic nature of PCa. 7 However, the mechanisms that account for decreasing DKK1 expression in PCa bone metastases are unknown.
Parathyroid hormone (PTH)-related protein (PTHrP), a peptide hormone that shares biological activity with PTH, has been shown to mediate both bone catabolic (that is, bone resorptive) and bone anabolic (that is, bone productive) effects in multiple cancers, including PCa. [8] [9] [10] [11] PTHrP is produced by PCa cells, and its expression increases as PCa progresses to the metastatic state. 12, 13 PTHrP has been associated with cancer progression, including metastasis. 14 The observation that PTHrP expression increases and DKK1 expression decreases during progression of PCa to osteoblastic metastases led us to explore whether the osteoblastic activity of PCa is dependent on PTHrP-mediated regulation of DKK1 expression.
RESULTS

PTHrP modulates DKK1 expression in PCa cells
Although the expression of DKK1 is high in primary PCa, it decreases as PCa metastasizes to bone. 7 In contrast, PTHrP expression in PCa metastases becomes elevated as PCa histological grade progresses. 13, 15 To explore whether PTHrP could regulate DKK1 expression to account for the inversely related expression of PTHrP and DKK1, we treated PC-3 cells and PC-3M cells, a highly metastatic variant PC-3, with PTHrP and checked the DKK1 expression. PTHrP Figure 1A) .
PTHrP modulates transcriptional activity of genes through the AP-1 transcription factor composed of heterodimers and homodimers of c-Jun and c-Fos family members. 16 This suggests that PTHrP may modulate DKK1 expression through c-Jun and c-Fos family members. In addition, b-catenin, which modifies activity of several transcription factors, induces DKK1 expression, which gives rise to the possibility that PTHrP downregulates DKK1 expression through modulation of b-catenin. Figure 1A) . Similarly, PTHrP (10
increased c-Jun protein expression as soon as 4 h after treatment and maintained the increase through 16 h (Figure 1g ). To extend our findings to an additional cancer type that commonly metastasizes to bone, we also evaluated the MDA-MB231 breast cancer cell line. PTHrP induced similar effects in the MB231 cells on DKK1 and c-Jun (Supplementary Figure 1B) . In summary, PTHrP induced an increase in c-Jun expression that was associated with a decrease in DKK1 expression in multiple cell lines.
Although PTHrP did not alter b-catenin levels, to exclude the possibility that PTHrP induced translocation of b-catenin from cytoplasm to nucleus a procedure of protein extraction from cytoplasmic and nuclear fraction were performed in PC-3, PC-3M, DU145 and MDA-MB231 cell lines. The results showed no significant change in the amount of b-catenin from either cytoplasmic or nuclear fraction between the different time course of PTHrP treatment (Figures 1d and f, and Supplementary Figures  1C and D) . These results indicated that PTHrP decreased DKK1 expression independent of b-catenin translocation from the cytoplasm to nucleus.
PTHrP mediates its activity, in part, through induction of cAMP. Forskolin can be used to mimic PTHrP activity through cAMP induction. 17, 18 To provide support for the possibility that PTHrP mediates downregulation of DKK1 expression through this classical cAMP-mediated pathway, we treated PC-3 cells with forskolin and evaluated DKK1 mRNA expression. Forskolin diminished DKK1 mRNA expression ( Figure 1h ) consistent with the concept that DKK1 expression is downregulated via the classical PTHrP-mediated protein kinase A/cAMP signaling.
The results, thus far, indicated that PTHrP was functioning in the PCa cell lines. However, in a previous study PTH/PTHrP receptor (PPR) was not found by northern blot, and it was observed that PTH(1-34) fragment did not bind to PC-3 cells, suggesting that PPR was not present. 12 In contrast, several other groups identified PTHrP is functional in PC-3 cells and identified PPR in clinical PCa tissues. 19, 20 To clarify the expression of PTHrP receptor in the cell lines used, we first authenticated the cell lines we used by subjecting them to short tandem repeat DNA analysis, which confirmed their identity (Supplementary Table 1 ). We then evaluated the cells for PPR protein expression using HEK293T cells derived from human embryonic kidney cells as a positive control. 21 PPR was identified as only one band of around molecular weight 82 kDa in all cell lines (Supplementary Figure 1E) . In addition to confirming its presence, we wanted to confirm that PPR was functional based on classic criteria of PPR activation, that is, induction of cAMP, in these cell lines. To perform this, cells were exposed to PTHrP and induction of cAMP was measured. After normalization for unstimulated cAMP levels using a control group, PTHrP induced cAMP levels in all cell lines in a dose-responsive fashion (Supplementary Figure 1F) . Taken together, the presence of PPR protein expression and induction of cAMP indicate that PCa cells express functional PPR.
PTHrP knockdown increased DKK1, and not b-catenin or TCF4 As the presence of functional PPR was confirmed, we further explored the mechanism through which PTHrP modulated DKK1 expression. Endogenous PTHrP was knocked down in PC-3M cells, and c-Jun and DKK1 expressions were evaluated. Knockdown of PTHrP, using two different short hairpin RNAs, decreased c-Jun and increased DKK1 protein levels with no impact on total b-catenin levels (Figure 2a ). To determine whether knocking down of PTHrP impact the intracellular localization of b-catenin, cytoplasmic and nuclear extract was isolated from the stably transfected scrambled and PTHrP short hairpin RNA cell lines. Knockdown of PTHrP had no impact on cytoplasmic or nuclear b-catenin levels (Figure 2b The observation that DKK1 expression was decreased through PTHrP-mediated induction of c-Jun suggested that PTHrP has an effect on DKK1 promoter activity, as DKK1 expression was impacted at the mRNA level and c-Jun is a transcription factor. Accordingly, we assessed whether PTHrP inhibited DKK1 expression through repression of the DKK1 promoter. A 3Kb DNA fragment of the DKK1 promoter 5 0 upstream of the DKK1 transcription initiation site was cloned (pGL3-DKK1p-Luc reporter) using PC-3M genomic DNA as a template, and then was used to evaluate the effect of PTHrP on its activity. Consistent with their effect on DKK1 expression, both PTHrP and forskolin inhibited basal DKK1 promoter reporter activity by B70% (Figure 2d ).
As PTHrP repressed basal DKK1 promoter activity, we next wanted to determine whether PTHrP could repress induced DKK1 promoter activity. Canonical Wnt signaling mediates its transcriptional activity through promoting b-catenin-mediated activation of transcription factor activity. Thus, we first evaluated whether b-catenin could induce DKK1 promoter activation. To perform this, a b-catenin expression plasmid was cotransfected with the pGL3-DKK1p-Luc reporter in 293T cells (the degree of ectopic expression of b-catenin is shown in Supplementary Figure 2C) . The b-catenininduced promoter activity by approximately fourfold within 24 h (Figure 2e ). These results indicated that b-catenin activates the DKK1 promoter.
The observation that PTHrP was able to block DKK1 promoter activation (Figure 2d) , combined with the observation that it does not alter b-catenin expression (Figure 2a ), suggests that PTHrP mediates its activity on the DKK1 promoter independent of regulating b-catenin expression. To provide further support for the ability of PTHrP to impact the promoter activity independent of a requirement for changing b-catenin expression, we stably transfected b-catenin into PC-3M cells and evaluated the impact of PTHrP on DKK1 promoter activity in these cells. Overexpression of b -catenin in PC-3M increased both DKK1 and c-JUN protein level, whereas PTHrP increased the c-Jun but decreased the DKK1 level in both PC-3M/v and PC-3M/b-catenin cell (Figure 2f ).
Overexpression of b-catenin induced DKK1 reporter activity by more than 3.5-fold compared with control-transfected cell lines (Figure 2g ). Addition of PTHrP inhibited b-catenin-induced DKK1 promoter activity by B38% (Figure 2g ). These results indicated that even in excess of b-catenin expression, PTHrP can suppress DKK1 promoter activity. PTHrP may achieve this effect through either impacting the DKK1 promoter independently of any effect on b-catenin or through inhibiting b-catenin's function on the promoter.
PTHrP inhibits DKK1 expression through WRE motifs in the DKK1 promoter The above findings are consistent with PTHrP inhibiting b-cateninmediated activation of the DKK1 promoter independent of changes in b-catenin levels. This may occur either through PTHrP promoting binding of inhibitory transcription factors to the promoter, inducing the release of activating transcription factors from the promoter or competing with b-catenin on Wntresponsive elements (WRE). To explore for this latter possibility, we initially set out to identify potential cis-acting sites through which PTHrP could interfere with b-catenin-induced activation of the DKK1 promoter. Accordingly, the 3-Kb DKK1 promoter was serially deleted to 1.8, 1.0 and 0.5 Kb (Figure 3a ). In addition, transcription element analysis (http://www.cbil.upenn.edu/cgi-bin/ tess/tess) was performed to identify putative WRE (that is, TCF/bcatenin binding sites) in the 3-Kb DKK1 promoter fragment. Five putative sites were identified and then mutated using site-directed mutagenesis (sites indicated in Figure 3a ). All mutant promoter reporters were cotransfected with b-catenin plasmid (or empty vector control), and promoter activity was quantified. The largest deletion (delK/KA construct) resulted in reduction of b-catenin-induced promoter activity by 60%. It should be noted that this deletion did not include the most proximal two putative WRE sites (sites 1 and 2). Mutation, specifically of site 2 (Mut2 construct), reduced the b-catenin-induced promoter activity by B90% (Figure 3a) , whereas mutation of site 1 reduced the promoter activity by B70%. These results indicate that site 2 is the main mediator of b-catenin-induced DKK1 promoter activation, albeit other sites contribute to the overall activity.
TCF4 is a Wnt-responsive transcription factor that binds onto its WRE in a non-active fashion. Upon stimulation by Wnts, b-catenin translocates to the nucleus and promotes transcriptional activation through changing the conformation of TCF4 to an active state. To further explore if DKK1 expression is mediated through this classical Wnt pathway, we knocked down TCF4 expression. Knockdown of TCF4 decreased DKK1 expression in PC-3M cells (Figure 3b ), indicating that DKK1 is regulated by TCF4. To determine whether b-catenin-induced DKK1 expression was mediated through TCF activation of the DKK1 promoter, we coexpressed b-catenin and TCF4, or dominant-negative TCF, and measured the activation of the DKK1 promoter (TCF protein levels are shown in Supplementary Figure 2A ). TCF4 stimulated bcatenin-induced expression of the DKK1 promoter, whereas dominant-negative TCF4 blocked b-catenin-induced activation of the DKK1 promoter ( Figure 3c ). In contrast, neither b-catenin, TCF4 nor dominant-negative TCF had an effect on the WRE-2 mutant promoter ( Figure 3c ). Taken together, these results indicate that TCF4/b-catenin mediates activation of the DKK1 promoter through TCF4 activity on the WRE-2 element.
To determine whether PTHrP inhibits the DKK1 promoter through activity on the WRE-2 element, PC-3M/v and PC-3M/bcatenin stable cell lines (as shown in Figure 2f ) were transfected with wild type or WRE mutant reporters, and then treated with 10 À 7 M PTHrP for 24 h. b-catenin activated the wild type and all mutant reporters, except the WRE-2 mutant. PTHrP decreased bcatenin-induced DKK1 promoter activation by 1.5-to 2-fold, except in the WRE-2 mutant (Figure 3d ). This indicates that PTHrP mediates its inhibitory effect on the DKK1 promoter through the WRE-2 site.
c-Jun downregulates DKK1 expression through WRE-2 in DKK1 promoter The observation that PTHrP induces c-Jun, while decreasing DKK1 expression, is consistent with the possibility that PTHrP mediates repression of DKK1 expression through c-Jun. Thus, to determine whether PTHrP mediates its activity on the DKK1 promoter through c-Jun, we examined the effect of several mutated forms of c-Jun on their ability to impact DKK1 promoter reporter activity (Supplementary Figure 2B) . The c-Jun mutated forms used were as follows: TAM67, a dominant-negative form of c-Jun due to deletion of the transactivation domain; DBM3, which contains a mutated DNA binding domain due to insertion of five amino acids (EEGIE); and LZM, that contains a deletion of the leucine zipper domain, which destroys the ability of c-Jun to dimerize. 22, 23 To test the effects of c-Jun and its mutants on DKK1 reporter activities, the plasmid, pGL3-DKK1p-luc with 3 Kb DKK1 promoter-driven luciferase, was used as a reporter. We used the transcription factor SOX9, a known inhibitor of b-catenin signaling pathway, 24 as a control for inhibition of the DKK1 promoter reporter. We used SP1, which has no known interaction with b-catenin signaling, as a negative control. We first confirmed SP1, SOX9 and b-catenin overexpression (Supplementary Figure 2C) . SP1 had no effect on b-catenin-induced activation of the DKK1 promoter in 293T cells, whereas SOX9 and c-Jun reduced b-catenin-mediated activation of the DKK1 promoter by B50% and 80%, respectively (Supplementary Figure 2D) . These results indicate that both SOX9 and c-Jun inhibit b-catenin-induced activation of the DKK1 promoter.
To confirm the ability of c-Jun to inhibit DKK1 promoter activity, 293T cells were transfected with plasmids that express the various c-Jun forms. Proteins were of the expected sizes (Supplementary Figure 2E) . The 293T cells were cotransfected with either pcDNA3-b-catenin or pcDNA3 empty vector combined with the various c-Jun constructs. c-Jun inhibited basal promoter activity by 60%, whereas Tam67 and LZM constructs had no effect, and DBM3 actually enhanced the reporter activity 2.2-fold compared with À 7 M PTHrP for the indicated times followed by cytoplasmic extract (CE) and nuclear extract (NE) isolation. The CE and NE were loaded and separated on 10% SDS-PAGE gels. The membrane was probed using the indicated antibodies. (e) PC-3cells were treated with 0 (vehicle control), 10
À 7 and 10 À 6 M PTHrP for 8 h. Total cell lyste was separated by SDS-PAGE, and membranes were probed with antibodies as labeled. (f ) PC-3 cells were treated with 10 À 7 M PTHrP for the indicated times followed by CE and NE isolation. The CE and NE were loaded and separated on 10% SDS-PAGE gels. The membrane was probed using the indicated antibodies. that by an empty vector control (Figure 4a ). In addition to impacting basal promoter activity, c-Jun inhibited, whereas DBM3 and LZM promoted, b-catenin-induced DKK1 promoter activation. Tam67 had minimal impact on DKK1 basal or induced activity. Taken together, these results provide further evidence that c-Jun inhibits both basal and b-catenin-mediated activation of the DKK1 promoter.
To determine whether c-Fos, another transcription factor that can be a component of AP-1, has a role in DKK1 expression, c-Fos was overexpressed (as were c-Jun and Tam67 as positive and negative controls, respectively) in 293T cells transfected with the DKK1 3-Kb promoter reporter. We first confirmed that c-Fos protein was expressed (Supplementary Figure 2C) . We then confirmed that c-Jun and c-Fos were functional, by using a pAP1-luc reporter assay in 293T cells. Both JUN and FOS constructs activated the AP-1 reporter, whereas Tam67 did not (Supplementary Figure 2F) . Neither c-Fos nor Tam67 had an impact on b-catenin-mediated activation, whereas c-Jun inhibited Figure 2G) . Taken together, these results confirm that the c-Jun, but not the c-Fos component of AP-1, inhibits DKK1 promoter activity. To delineate the specific response elements on the promoter where c-Jun mediates its activity, we used the promoter reporter mutants (as originally described in Figure 3a ) and tested their activity using various combinations of control vectors or b-catenin expression vectors with JUN or Tam67 expression vectors. c-Jun inhibited b-catenin-induced activation of all three progressively deleted DKK1 promoter mutants (Figure 4b ). However, although c-Jun inhibited b-catenin-induced activation of promoters containing point mutations at sites 1, 3, 4 and 5, it had no effect on the promoter containing point mutation at site 2 ( Figure 4c ). These results demonstrate that c-Jun mediates its inhibitory activity through site 2 of the DKK1 promoter. These results also correspond with our earlier finding that site 2 is critical for b-catenin-mediated induction of the DKK1 promoter ( Figure 3) .
In order to determine whether the ability of c-Jun to inhibit b-catenin-mediated activation of DKK1 was specific to the DKK1 promoter or a more general effect, we tested whether c-Jun could block b-catenin-mediated activation of the TCF binding promoter that is known to be activated by b-catenin. To perform this, we used the Topflash construct that contains three WRE element sites and Fopflash, in which these sites are mutated so as to be nonfunctional, as a negative control. c-Jun inhibited b-cateninmediated activation of Topflash by B80%, whereas Tam67 had no effect (Figure 4d ). Neither c-Jun nor Tam67 had an impact on Fopflash (not shown). These results indicate that c-Jun's ability to inhibit b-catenin-mediated activation of promoters is a general effect on WREs.
As b-catenin promotes activation through forming a complex with TCF4 on the WRE, we wanted to determine whether c-Jun inhibited the ability of TCF4, in addition to b-catenin, to activate the DKK1 promoter. First, we tested the effect of c-Jun on the delKp-luc DKK1 reporter that contains the wild-type site 2. c-Jun blocked the activation caused by either TCF4 or b-catenin alone (Figure 4e ), but mutation of the WRE motif site 2 eliminated the activation caused by either TCF4 and/or b-catenin, and also blocked the ability of c-Jun to inhibit the promoter (Figure 4f ). These results demonstrated that c-Jun inhibition of DKK1 activation is a broad effect. This led us to explore the mechanism underlying the crosstalk of c-Jun and TCF4/b-catenin signal transduction.
PTHrP inhibits DKK1 expression through c-Jun in PCa
To confirm that c-Jun's activity on the DKK1 expression extended to PCa cell lines and through use of stable expression of proteins, Figure 3A) and protein expression (Figure 5a ). None of these factors altered total cellular b-catenin expression. We also noted that endogenous c-Jun was decreased in the Tam67-transduced cells. The reason for this is likely that c-Jun upregulates its own expression, 22, 23 thus blocking its activity with Tam67 results in lower c-Jun expression. These results were consistent with previous reporter assays in 293T cells and indicate that c-Jun inhibits endogenous DKK1 expression in PC-3M cells.
To determine whether c-Jun impacts b-catenin-induced DKK1 promoter activation in PCa cells, control vector or b-catenin were cotransfected into the stably transformed PC-3M cell lines. c-Jun inhibited, whereas blocking endogenous c-Jun with DBM3 or Figure 3B) and protein expression, respectively (Figure 5c ). To evaluate the effect of Jun on intracellular localization of b-catenin, cytoplasmic and nuclear extracts of these stably transfected cell lines were compared. Neither Jun nor Tam67 didn't altered the b-catenin level in the cytoplasm or nucleus (Figure 5d ). We also evaluated the impact of c-Jun on DKK1 protein expression in another PCa cell line, Du145 cells, and observed results similar to those as in PC-3M (Supplementary Figures 3C and D) . Taken together, these results indicate that c-Jun inhibits basal and b-catenin-induced DKK1 promoter activity, and its resulting mRNA production and protein expression in PCa cells, and are consistent with the results observed in the 293T cells.
Although it was demonstrated that c-Jun inhibits DKK1 expression at the transcriptional level, it was not clear that PTHrP inhibited DKK1 expression through c-Jun. To confirm that PTHrP downregulates DKK1 expression through c-Jun, the stably transduced cell lines PC-3M/V, PC-3M/Myc-JUN and PC-3M/MycTam67 were treated with PTHrP. c-Jun moderately enhanced PTHrP-mediated inhibition of DKK1 mRNA expression, whereas Tam67 completely blocked it (Figure 5e ). To further evaluate the requirement for c-Jun to mediate PTHrP's inhibitory effect, we first knocked down c-Jun expression in PC-3M cells, which resulted in an increase of endogenous DKK1 mRNA (Supplementary Figure 3E) and protein (Figure 5f ). In the presence of control siRNA, PTHrP inhibited DKK1 mRNA expression, whereas when c-Jun was knocked down PTHrP had no effect on DKK1 mRNA expression (Figure 5g Figure 6a ). To determine whether there was a difference between c-Jun and Tam67 association with b-catenin, stable cell lines expressing either flag-tagged c-Jun or flag-tagged Tam67 were used for CO-IP. More b-catenin protein was coprecipitated with flag-c-Jun than with Flag-Tam67, whereas the blotting indicated that the amount of input protein for all samples was similar (Figure 6b ). These results demonstrate that c-Jun binds b-catenin, whereas Tam67 has less affinity for b-catenin.
To determine whether c-Jun and b-catenin interact on the DKK1 promoter, ChIP assay was performed with different treatments. Primers to amplify À 200 to À 100 bp region in DKK1 promoter were used to check the DNA fragments after ChIP. This fragment covered site 2, which we determined above is a critical WRE. In (Figure 7a ). We next wanted to determine whether PTHrP inhibition of b-catenin activity extends to other promoters besides DKK1. AXIN2 is an inhibitor of the Wnt signaling pathway, through its ability to promote degradation of b-catenin, resulting in a negative feedback loop because b-catenin activates the AXIN2 promoter. 25 In addition, MYC is a known b-catenin target gene. 26 Accordingly, the ChIP assay was repeated using the AXIN2 and MYC WREs as target DNAs. PTHrP inhibited ChIP of both AXIN2 (Figure 7b ) and MYC (Supplementary Figure 4A ) WREs when b-catenin antibody was used. Similar to the ChIP studies using the DKK1 DNA promoter target, c-Jun overexpression increased and Tam67 overexpression blocked the PTHrP-mediated inhibition of b-catenin binding to both the AXIN2 and MYC WREs. These results indicate that PTHrP promotes binding of c-Jun to the b-catenin/WRE complex of multiple promoters in PCa cells.
In order to fully activate a target promoter, b-catenin binds to promoter-bound transcription factor TCF4. This raises the possibility that c-Jun inhibits DKK1 promoter activity through competing with b-catenin for binding to TCF4. To test this possibility, re-ChIP assay was performed using anti-TCF4 as the first ChIP antibody, followed by anti-c-Jun or anti-b-catenin antibodies in PC-3M cells. Using TCF4 as the first antibody, we found that re-ChIP with either anti-b-catenin or anti-Jun resulted in ChIP of the DKK1 WRE (Figure 7c ). This indicated that both b-catenin and c-Jun bind the same TCF4/WRE complex. To confirm that the interaction of c-Jun and the b-catenin/TCF4 complex happened on TCF binding motifs in DKK1 promoter region, ChIP assays were employed with Jun, b-catenin or TCF4 knockdown PC-3 cell lines (knockdowns shown in Figures 3b and 5e) . Knockdown of c-Jun resulted in more anti-b-catenin ChIPed DKK1 WRE-2 promoter fragments compared with that in siLuc (control), b-catenin or TCF4 knockdown groups; TCF4 knockdown decreased the amount of DKK1 WRE elements ChIPed by either b-catenin or c-Jun (Figure 7d ). This indicates that c-Jun does interfere with b-catenin/TCF4 on the WRE-2 of DKK1. To confirm that PTHrP-mediated inhibition of DKK expression through the b-catenin/TCF4/WRE complex was not specific to the PC-3M cell line, we performed ChIP assays using Du145 and MDA-MB231 cells following PTHrP treatment. PTHrP decreased both ChIPed DKK1 and AXIN2 compared with control-treated groups (Supplementary Figures 4B and C, respectively) . These results indicate that c-Jun was dynamically binding with b-catenin on the TCF4/DNA platform. This observation, along with the previous result that both PTHrP administration, which increases c-Jun, and overexpression of c-Jun result in decreased binding of b-catenin to the WRE-2 promoter fragment (Figures 6d and 7a) indicate that c-Jun competes with b-catenin for binding to the TCF4/WRE complex in multiple cell lines.
DISCUSSION
PCa has underlying osteolytic activity, 2 yet it ultimately develops an overall osteoblastic phenotype. We previously reported that DKK1 expression decreases in clinical bone metastases and that loss of DKK1 contributes to the development of osteoblastic bone lesion. 6 However, the mechanism through which DKK1 expression decreases was unknown. The current study provides novel insight into the regulation of DKK1 expression in PCa and demonstrates novel crosstalk between PTHrP and the Wnt pathways to modulate DKK1 expression. Specifically, PTHrP was found to inhibit DKK1 expression through c-Jun-mediated inhibition of bcatenin activity on the DKK1 promoter. Overexpression of PTHrP was first identified in squamous cell carcinoma and associated with inducing marked bone resorption and hypercalcemia of malignancy. 27 Similarly, PTHrP expression has been shown to increase with PCa progression in bone. 12, 28, 29 However, unlike squamous cell carcinoma increased PTHrP in PCa is not associated with hypercalcemia, but is rather associated with classical osteoblastic lesions 9 ). Thus, it is possible that depending on the tumor context, PTHrP may induce a bone anabolic effect. Although induced overexpression of PTHrP in PCa cells induces osteolytic lesions, 30 it is unclear what role of endogenous PTHrP expression has on bone remodeling in the context of the PCa. It is plausible that endogenous PTHrP expression in clinical PCa has a bone anabolic effect, similar to PTH. This possibility is consistent with the observation that PTHrP expression increases as PCa progresses to bone metastases, which are osteoblastic. 13, 31 Our findings suggest that upregulation of PTHrP expression results in inhibition of DKK1 expression at the bone metastatic site, which allows for Wnt-mediated osteoblastic activity.
Our observation that PTHrP downregulates DKK1 expression in PCa cells is consistent with the action of two other bone anabolic factors, endothelin-1 and transforming growth factor-b1, which were shown to decrease DKK1 expression in primary murine osteoblasts and human endometrial stromal cells, respectively. 32, 33 The molecular mechanism resulting in decreased DKK1 expression in these models is unknown. Our study sheds light on a novel molecular mechanism through which a bone anabolic factor transcriptionally regulates a Wnt pathway inhibitor to allow the bone anabolic activity of Wnt to be realized.
In addition to our finding that PTHrP, through c-Jun, inhibits DKK1 promoter activity, several other mechanisms have been identified that repress DKK1 expression, including epigenetic silencing in gastrointestinal, colonic and ovarian cancers, [34] [35] [36] and through the activity of miR-335-5p 37 in normal bone. In addition, several oncogenic transcription factors have been shown to repress DKK1 expression, including c-MYC in mammary epithelial cells, 38 MYCN in neuroblastoma, 39 GATA6 in pancreatic cancer 40 and EWS/FL1 in Ewing's sarcoma. 41 Our data are the first to link the PTHrP pathway and its downstream proto-oncogene effector, c-Jun, with the Wnt pathway modulation through regulation of the DKK1 promoter.
In contrast to our findings, c-Jun has been previously shown to increase DKK1 expression during apoptosis that occurs concomitant with vertebrate limb development. 42 In that study, overexpression of c-Jun through electroporation into limb buds induced DKK1 expression based on in situ hybridization. In addition, DKK1 expression was decreased in mouse embryonic fibroblasts derived from c-Jun knockout mice compared with wildtype mice. Although it is not clear how c-Jun can mediate DKK1 expression in this instance as opposed to inhibiting, as we observed in PCa, it is possible that either tissue specificity or the context of development versus cancer accounts for this difference. In addition, technical differences may account for the conflicting results. For example, in the previous report evaluation of DKK1 was semiquantitative and not confirmed at protein or promoter levels. Our findings are consistent with previous reports that have demonstrated c-Jun can inhibit transcription activation complexes, such as those containing MyoD 43 or Smad3, 44 and identify a novel interaction of c-Jun as an inhibitor of the b-catenin/TCF4 transcriptional activation complex.
The majority of cancers that metastasize to bone induce osteolytic lesions, whereas PCa is unique, as it induces primarily osteoblastic lesions. 1 Although not clearly defined, multiple mechanisms have been demonstrated to contribute to the promotion of osteoblast activity. PCa produces a variety of factors that stimulate osteoblast growth and differentiation, including, but not limited to, fibroblast growth factor, 45 bone morphogenetic proteins, 46, 47 endothelin-1 48 and vascular endothelial growth factor. 49 In addition to these factors, we had previously demonstrated that PCa produces Wnts, which contribute to PCa-mediated osteoblastic activity. 6 We also identified that their endogenous Wnt activity was inhibited, as they also expressed DKK1. Analysis of clinical PCa tissues demonstrated that DKK1 expression decreased as PCa progressed towards osteoblastic metastases. 7 The mechanism through which DKK1 expression decreased was unknown. The current study provides a mechanism that accounts for this clinical observation. Namely, PTHrP mediates the downregulation of DKK1, which then allows for Wnts to be active and induce osteoblast growth and differentiation.
In summary, our study offers a novel paradigm underlying PTHrP and DKK1, and their role in PCa bone metastasis. We identified novel crosstalk between PTHrP and the Wnt pathways in PCa and the molecular mechanism that achieves this activity. Specifically, the crosstalk requires PTHrP-mediated induction of c-Jun, which then interacts with b-catenin and blocks transcription of DKK1. Defining mechanisms through which PCa changes the tumor microenvironment is critical toward defining therapeutic targets for prevention and therapy of PCa bone metastases. Our findings indicate a new mechanism to account for how PCa induces a reactive bone microenvironment, and these findings offer several signaling pathways to exploit for therapeutic benefits.
MATERIALS AND METHODS
Cell lines
PC-3, PC-3M, Du145 PCa cells and MDA-MB231 cell were maintained in 10% fetal bovine serum, RPMI 160 medium at 37 1C in a 5% CO2/95% air atmosphere. The PC-3M cell line was derived by injecting PC-3 cells into the spleen of a nude mouse and isolating a cell line from a liver metastasis. 50 The identity of all cell lines used in this study were confirmed using short tandem repeat profiling (Supplementary Table 1) , to ensure the short tandem repeat profiles matched previous reports or the ATCC collection. 51, 52 The 293T cells were maintained in 10% fetal bovine serum, Dulbecco's modified Eagle's medium with high glucose at 37 1C in a 5% CO2/95% air atmosphere.
Stable cell lines were produced via transduction of cells using retrovirus or lentivirus followed by antibiotic resistance selection for 2-4 weeks. RNA extraction and real-time PCR PTHrP (1-34) (H-9095, Bachem, Torrance, CA, USA) was dissolved in 4 mM HCl-1% bovine serum albumin, stock solution and kept at À 80 1C. Forskolin (F3917, Sigma, St Louis, MO, USA) was dissolved in dimethylsulfoxide. Cells (10 6 ) in culture media were treated with PTHrP indicated time and/or dose in figures. After incubation with PTHrP, total RNA was extracted using Qiagen RNeasy Kit (Qiagen Ltd, Valencia, CA, USA) followed the manufacturer's directions. Three micrograms of total RNA was used for reverse transcription using the Superscript first strand DNA synthesis kit (Invitrogen). Real-time PCR was performed with Qiagen SYBR Green Master Mix Kit using a Roche Light Cycler. The results of real-time PCR were analyzed using the À DDCt method.
Reporter luciferase assays
Cells plated in 12-well plates and incubated overnight, and were transfected with plasmids using Lipofectamine 2000 (Invitrogen) reagents according to the manufacturer's protocol. For DKK1 promoter reporter assay, 100 ng DKK1 promoter luciferase reporter were used per well. For Topflash or Fopflash reporter assay, 50 ng plasmids were used. To keep plasmid amount constant in each well, pCMV or pCDNA3 empty vector was added as appropriate. Luciferase and Renilla activity of total cell lysates were determined using the Dual Luc Kit (Promega, Madison, WI, USA), and b-galactosidase activity of total cell lysates were determined using the b-Gal Kit (Clontech, Mountain View, CA, USA).
ChIP, re-ChIP assay ChIP assays were performed using a ChIP assay system (Upstate Biotechnology, Lake Placid, NY, USA) according to the manufacturer's protocol. Cells were incubated with a dimethyl 3, 3 0 -dithiobispropionimidate-HCl (Pierce, Rockford, IL, USA) solution (5 mmol) for 30 min on ice followed by formaldehyde treatment. For each ChIP reaction, 2 Â 10 6 cells were used. All precipitated DNA samples were quantified using real-time PCR. Data are expressed as the percentage of input DNA. For re-ChIP assays, 1 Â 10 7 cells were used for the first-step ChIP, then quantitative PCR was used to determine the difference between the samples using primers. Anti-c-Jun (sc-44), anti-b-catenin (07-1653; Millipore, Billerica, MA, USA) and anti-TCF4 (Clone 6H5-3; Millipore) were used for ChIP and re-ChIP assays.
Western blotting, IP and antibodies Cells were split and maintained in full medium 24 h before treatment. Cells were treated with 10 À 8 , 10 À 7 or 10 À 6 M PTHrP for 8 h (for dose-response experiments) or 10 À 7 M PTHrP for 0, 4, 8 and 16 h for time courses. Cells were washed with cold phosphate-buffered saline and the cell pellet was lysed with RIPA buffer (25 mM Tris-HCl pH 8.0, 50 mM NaF, 1% Igepal CA-630, 1% sodium deoxycholic acid, 10 mM NaHPO4, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 0.2 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride and 1 Â proteinase inhibitor cocktail) (Sigma). Protein concentration was measured using the BCA Kit (Pierce). Protein samples were prepared with 3 Â loading buffer (10% glycerol, 6%SDS, 5% 2-mercaptoethanol and 0.1% bromophenol blue), and boiled at 100 1C for 5 min before being loaded onto SDS-polyacrylamide gel electrophoresis gels. Semidry transfer blotting was performed using the manufacturer's recommendations. Polyvinylidene difluoride membranes were blocked with 5% non-fat milk-TBST (Tris-Buffered Saline and Tween 20) buffer or 5% bovine serum albumin-TBST buffer for 1 h. Primary antibody was added to block buffer overnight on a shaker at 4 1C. Horseradish peroxidase (HRP)-conjugated secondary antibodies were added and incubated for 1 h at room temperature. Electrochemiluminescence was performed according the standard protocol with the Supersignal Detection Kit (Pierce).
Endogenous CO-IP was performed to determine the interaction of proteins. PC-3 or PC-3M, and their derivative cells, were plated in 150 mm dishes, 2-5 Â 10 7 cells were collected and lysed in lysis buffer (25 mM HEPES, pH 7.9, 0.5% Chaps, 0.5% NP-40, 150 mM NaCl, 20 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride and 1 Â protease inhibitor cocktail) on ice for 2 h. Supernatants were collected after 14 000 r.p.m. 10 min centrifuge, and diluted with IP buffer (25 mM HEPES, pH 7.9, 0.5% Chaps, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride and 1 mM PIC). The diluted supernatant was precleared with 60 ml 50% slurry protein A/G agarose beads (Pierce) for PTHrP modulates DKK1 through Jun-interacting b-catenin H Zhang et al 2 h. Total 0.5 to 1 mg proteins were incubated with 2-5 mg antibody for each IP reaction on rotated routera overnight at 4 1C. Fifty microliter of 50% slurry protein A/G agarose beads were added to the reaction tube and rotated for another 2 h and then washed with IP buffer twice, phosphatebuffered saline twice, and finally 50 ml 3 Â SDS loading buffer was added to elute for western blotting.
The following antibodies were used for CO-IP or western blotting: Anti 
Statistical analyses
A one-way analysis of variance analysis was used with Bonferroni's post hoc analysis for comparison between multiple groups. A Student's t-test was used for comparison between two groups. Significance was defined as a Pvalue of o0.05.
